Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Progress and harmonization of gene editing to treat human diseases : Proceeding of COST Action CA21113 GenE-HumDi. / Cavazza, Alessia; Hendel, Ayal; Bak, Rasmus O.; Rio, Paula; Güell, Marc; Lainšček, Duško; Arechavala-Gomeza, Virginia; Peng, Ling; Hapil, Fatma Zehra; Harvey, Joshua; Ortega, Francisco G.; Gonzalez-Martinez, Coral; Lederer, Carsten W.; Mikkelsen, Kasper; Gasiunas, Giedrius; Kalter, Nechama; Gonçalves, Manuel A.F.V.; Petersen, Julie; Garanto, Alejandro; Montoliu, Lluis; Maresca, Marcello; Seemann, Stefan E.; Gorodkin, Jan; Mazini, Loubna; Sanchez, Rosario; Rodriguez-Madoz, Juan R.; Maldonado-Pérez, Noelia; Laura, Torella; Schmueck-Henneresse, Michael; Maccalli, Cristina; Grünewald, Julian; Carmona, Gloria; Kachamakova-Trojanowska, Neli; Miccio, Annarita; Martin, Francisco; Turchiano, Giandomenico; Cathomen, Toni; Luo, Yonglun; Tsai, Shengdar Q.; Benabdellah, Karim.
I: Molecular Therapy Nucleic Acids, Bind 34, 102066, 2023.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Progress and harmonization of gene editing to treat human diseases
T2 - Proceeding of COST Action CA21113 GenE-HumDi
AU - Cavazza, Alessia
AU - Hendel, Ayal
AU - Bak, Rasmus O.
AU - Rio, Paula
AU - Güell, Marc
AU - Lainšček, Duško
AU - Arechavala-Gomeza, Virginia
AU - Peng, Ling
AU - Hapil, Fatma Zehra
AU - Harvey, Joshua
AU - Ortega, Francisco G.
AU - Gonzalez-Martinez, Coral
AU - Lederer, Carsten W.
AU - Mikkelsen, Kasper
AU - Gasiunas, Giedrius
AU - Kalter, Nechama
AU - Gonçalves, Manuel A.F.V.
AU - Petersen, Julie
AU - Garanto, Alejandro
AU - Montoliu, Lluis
AU - Maresca, Marcello
AU - Seemann, Stefan E.
AU - Gorodkin, Jan
AU - Mazini, Loubna
AU - Sanchez, Rosario
AU - Rodriguez-Madoz, Juan R.
AU - Maldonado-Pérez, Noelia
AU - Laura, Torella
AU - Schmueck-Henneresse, Michael
AU - Maccalli, Cristina
AU - Grünewald, Julian
AU - Carmona, Gloria
AU - Kachamakova-Trojanowska, Neli
AU - Miccio, Annarita
AU - Martin, Francisco
AU - Turchiano, Giandomenico
AU - Cathomen, Toni
AU - Luo, Yonglun
AU - Tsai, Shengdar Q.
AU - Benabdellah, Karim
N1 - Publisher Copyright: © 2023 The Author(s)
PY - 2023
Y1 - 2023
N2 - The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across countries. Recently, COST Action funded the “Genome Editing to treat Human Diseases” (GenE-HumDi) network, uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech firms, and patient advocacy groups. GenE-HumDi's primary objective is to expedite the application of genome editing for therapeutic purposes in treating human diseases. To achieve this goal, GenE-HumDi is organized in several working groups, each focusing on specific aspects. These groups aim to enhance genome editing technologies, assess delivery systems, address safety concerns, promote clinical translation, and develop regulatory guidelines. The network seeks to establish standard procedures and guidelines for these areas to standardize scientific practices and facilitate knowledge sharing. Furthermore, GenE-HumDi aims to communicate its findings to the public in accessible yet rigorous language, emphasizing genome editing's potential to revolutionize the treatment of many human diseases. The inaugural GenE-HumDi meeting, held in Granada, Spain, in March 2023, featured presentations from experts in the field, discussing recent breakthroughs in delivery methods, safety measures, clinical translation, and regulatory aspects related to gene editing.
AB - The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across countries. Recently, COST Action funded the “Genome Editing to treat Human Diseases” (GenE-HumDi) network, uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech firms, and patient advocacy groups. GenE-HumDi's primary objective is to expedite the application of genome editing for therapeutic purposes in treating human diseases. To achieve this goal, GenE-HumDi is organized in several working groups, each focusing on specific aspects. These groups aim to enhance genome editing technologies, assess delivery systems, address safety concerns, promote clinical translation, and develop regulatory guidelines. The network seeks to establish standard procedures and guidelines for these areas to standardize scientific practices and facilitate knowledge sharing. Furthermore, GenE-HumDi aims to communicate its findings to the public in accessible yet rigorous language, emphasizing genome editing's potential to revolutionize the treatment of many human diseases. The inaugural GenE-HumDi meeting, held in Granada, Spain, in March 2023, featured presentations from experts in the field, discussing recent breakthroughs in delivery methods, safety measures, clinical translation, and regulatory aspects related to gene editing.
KW - base editors
KW - COST
KW - delivery systems
KW - European Cooperation in Science and Technology
KW - GenE-HumDi
KW - genome editing
KW - MT: RNA/DNA Editing
KW - regulatory guidelines
U2 - 10.1016/j.omtn.2023.102066
DO - 10.1016/j.omtn.2023.102066
M3 - Review
C2 - 38034032
AN - SCOPUS:85176456320
VL - 34
JO - Molecular Therapy - Nucleic Acids
JF - Molecular Therapy - Nucleic Acids
SN - 2162-2531
M1 - 102066
ER -
ID: 384494770